Table 1.
Baseline characteristics of patients who had an exacerbation (N = 3,960)
| Age (years) | 64 (8) |
| Male (%) | 74 |
| Prebronchodilator FEV1 (L) | 1.07 (0.39) |
| Postbronchodilator FEV1 (L) | 1.29 (0.43) |
| Prebronchodilator FEV1 (% predicted) | 38 (12) |
| Postbronchodilator FEV1 (% predicted) | 47 (13) |
| Prebronchodilator FVC (L) | 2.60 (0.81) |
| FEV1/FVC | 0.42 (0.10) |
| GOLD stage (%) | |
| II | 43 |
| III | 46 |
| IV | 9 |
| BMI (kg/m2) | 26 (5) |
| Current smokers (%) | 29 |
| Smoking history (pack-years) | 49 (28) |
| COPD duration (years) | 10 (7) |
| Baseline LABA (%) | 64 |
| Baseline ICS (%) | 65 |
| Baseline ICS + LABA (%) | 53 |
| Baseline anticholinergic (%) | 46 |
| SGRQ total score, units | 47 (17) |
Data are mean (SD) (where shown)
FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, BMI body mass index, COPD chronic obstructive pulmonary disease, LABA long-acting β-agonist, ICS inhaled corticosteroid, SGRQ St. George’s Respiratory Questionnaire